Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of the Norgine Group. Norgine B.V., the primary subsidiary of the group, is a European specialist pharmaceutical company with operations throughout Europe, Australia and New Zealand. Peter also serves as the Chief Executive of Norgine Ventures, which provides financing solutions to innovative healthcare companies.
Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
In addition to his role at Norgine, Peter is a non-executive Director of Agendia N.V., a molecular diagnostics company based in Amsterdam.
Peter Martin is the Chief Operating Officer at Norgine.
Peter has worked in the pharmaceutical industry in Europe and the US for the past thirty-eight years in a variety of sales, research and development and senior marketing and general management roles. He held a number of senior positions at Schering-Plough including UK General Manager and Vice President of Marketing at Schering’s US operations. He later went on to become Director of Operations Northern Europe for the Italian pharmaceutical company Menarini International before joining Norgine as its Chief Operating Officer in 2004.
Peter is Chairman of Arc Medical Design Limited, a majority owned subsidiary of Norgine, and Chairman of SpineVision.
Peter has a keen interest in the interface between Industry, Patients’ Associations and the individual patient and is a strong proponent for improved relations between these parties.
Peter has served on the ABPI Board of Management on two separate occasions in the 1990s and 2000s and is vociferous in his support for small companies.
Peter has an MA in Chemistry from Oxford University and an MBA from the Open University.
Christopher Bath is the Chief Financial Officer at Norgine.
Chris has over 15 years’ experience in the pharmaceutical sector. He joined the Rothschild Healthcare Investment Banking team in 2000, having qualified as a Chartered Accountant with Arthur Andersen, and over the next 10 years worked on over 30 completed deals.
He left Rothschild to join a start-up specialist diagnostic imaging company, Nuada Medical, as CFO before joining Shire plc in 2012 as Head of M&A. While at Shire, Chris worked on a number of transactions, including the $4.2 billion acquisition of Viropharma Inc.
Chris originally trained as a scientist, reading Physics at Lady Margaret Hall, Oxford.
Paul Pay is the Chief Business Development Officer at Norgine.
Paul has over 35 years’ experience in the pharmaceutical industry in a range of commercial roles. These have covered sales, marketing, market research, licensing, business development and general management.
Paul joined Norgine in November 2002. Prior to that he worked for a number of companies covering Big Pharma (Wellcome, Fisons), “biotechs” (Xenova, Andaris) and a university spin-out (Aegis). He has worked in the UK and the USA.
Tara Barry is the Chief Human Resources Officer at Norgine.
Prior to joining Norgine in 2015, Tara has worked across a variety of industries for companies such Zurich Insurance, Hewlett Packard, Citigroup and Bertelsmann AG, as well as Roland Berger – Strategy Consultants.
During her twenty year career, Tara has lived and worked in Canada, the United States, Germany and Switzerland. Tara has a BA in Psychology from the University of Waterloo in Canada.
Kenneth Scrimgeour is the Chief Commercial Officer at Norgine.
Ken has worked in a variety of sales, marketing and general management roles in the pharmaceutical industry in Europe and the US for the past twenty-eight years; either in local roles or within regional and global positions. Ken has a BSc from Edinburgh University and he joined Norgine in 2004.
Philippe Caroff is the Chief Manufacturing Officer at Norgine.
Philippe joined Norgine in 2013 as Director for External Network, looking after all outsourced manufacturing activities and since mid-2015 has also taken responsibilities for Supply Chain & Distribution activities.
Prior to this, Philippe has worked for a number of companies including Ipsen, Cap Gemini, Seagram and BP, in various positions in Manufacturing, Supply chain, Purchasing activities and also in Research & Development, with more than 15 years in the Pharmaceutical industry. Philippe graduated from Ecole des Mines de St Etienne in General Engineering.
Alastair Benbow is the Chief Development and Medical Officer at Norgine.
Alastair is a physician with over 25 years of experience in the pharmaceutical industry.
Prior to joining Norgine in September 2016, Alastair worked for a number of companies including Fisons, Genentech, Synthelabo and spent 12 years working at GlaxoSmithKline (GSK). During his time at GSK, he held positions as UK Medical Director, Head of European Government Affairs, Head of Psychiatry Development, European Medical Director and SVP Global Safety and Pharmacovigilance and EU QPPV.
For three years, he held the role of Executive Director for the non-profit organisation, the European Brain Council and for three years he was Chief Medical Officer at Kinapse, where he led the Regulatory, Safety and Medical functions. He is a fellow of the Royal College of Physicians of Ireland and a Fellow of the Faculty of Pharmaceutical Medicine. In 2017 Alastair was appointed Chair of the Ethics and Practice Committee of the Faculty of Pharmaceutical Medicine.
We use strictly necessary, performance and functionality cookies to give you the best experience while using this website. We do not employ any marketing cookies on this website. Only continue if you accept. AcceptRead more